Who are Sanqi+Bingpian's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SaiLuoTong capsule, Shuxuening Injection, T89 Low dose, T89 high dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sanqi-bingpian.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sanqi+Bingpian — Competitive Intelligence Brief

Sanqi+Bingpian (Sanqi+Bingpian) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine compound. Area: Cardiovascular.

phase 3 Traditional Chinese medicine compound Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sanqi+Bingpian (Sanqi+Bingpian) — Tasly Pharmaceuticals, Inc.. Sanqi+Bingpian is a traditional Chinese medicine compound that has been studied for its potential anti-inflammatory and cardiovascular protective effects.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Sanqi+Bingpian TARGET	Sanqi+Bingpian	Tasly Pharmaceuticals, Inc.	phase 3	Traditional Chinese medicine compound
SaiLuoTong capsule	SaiLuoTong capsule	Shineway Pharmaceutical Co.,Ltd	phase 3	Traditional Chinese medicine compound
Shuxuening Injection	Shuxuening Injection	Beijing Tiantan Hospital	phase 3	Traditional Chinese medicine compound
T89 Low dose	T89 Low dose	Tasly Pharmaceuticals, Inc.	phase 3	Traditional Chinese medicine compound
T89 high dose	T89 high dose	Tasly Pharmaceuticals, Inc.	phase 3	Traditional Chinese medicine compound / Herbal extract

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine compound class)

Tasly Pharmaceuticals, Inc. · 2 drugs in this class
Beijing Tiantan Hospital · 1 drug in this class
Shineway Pharmaceutical Co.,Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sanqi+Bingpian — Competitive Intelligence Brief. https://druglandscape.com/ci/sanqi-bingpian. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab